Prevention of progression in Parkinson’s disease

Jan Aaseth · Petr Dusek · Per M. Roos

Received: 20 June 2018 / Accepted: 11 July 2018 / Published online: 20 July 2018
© The Author(s) 2018

Abstract Environmental influences affecting genetically susceptible individuals seem to contribute significantly to the development of Parkinson’s disease (PD). Xenobiotic exposure including transitional metal deposition into vulnerable CNS regions appears to interact with PD genes. Such exposure together with mitochondrial dysfunction evokes a destructive cascade of biochemical events, including oxidative stress and degeneration of the sensitive dopamine (DA) production system in the basal ganglia. Recent research indicates that the substantia nigra degeneration can be decelerated by treatment with iron binding compounds such as deferiprone. Interestingly compounds known to decrease PD risk including caffeine, niacin, nicotine and salbutamol also possess iron binding properties. Adequate function of antioxidative mechanisms in the vulnerable brain cells can be restored by acetylcysteine supplementation to normalize intracellular glutathione activity. Other preventive measures to reduce deterioration of dopaminergic neurons may involve lifestyle changes such as intake of natural antioxidants and physical exercise. Further research is recommended to identify therapeutic targets of the proposed interventions, in particular protection of the DA biosynthesis by oxygen radical scavengers and iron binding agents.

J. Aaseth
Research Department, Innlandet Hospital Trust, Brumunddal, Norway

J. Aaseth
Inland Norway University of Applied Sciences, Elverum, Norway

P. Dusek
Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University, Praha 2, Czech Republic

P. Dusek
General University Hospital in Prague, Prague, Czech Republic

P. Dusek
Department of Radiology, First Faculty of Medicine, Charles University, Praha 2, Czech Republic

P. M. Roos
Institute of Environmental Medicine, Karolinska Institutet, Solna, Sweden
e-mail: per.roos@ki.se

P. M. Roos
Department of Clinical Physiology, Capio St. Görans Hospital, Stockholm, Sweden

Springer
Keywords Substantia nigra · Dopamine · Iron · Copper · Oxidative stress · Metal binding

Introduction

Parkinson’s disease (PD) affects at least 6 million people worldwide (Kalia and Lang 2016) and typically occurs in people over the age of 60, of whom about one percent are affected (Global Burden of Disease Cancer et al. 2017). Life expectancy is moderately reduced yet PD mortality doubles some 15 years after the diagnosis. PD is a progressive disorder of the brain where dopamine-producing cells located in the substantia nigra (SN) degenerate. Dopamine (DA) synthesized in SN is an important neurotransmitter depleted both in PD and other movement disorders (Bernheimer et al. 1973). The precursor of DA known as L-dopa originates from the amino acid L-tyrosine through the action of the enzyme tyrosine hydroxylase that uses oxygen and iron (Fe) as cofactors (Fig. 1). Dopamine is transported extracellularly by the DA active transporter to synaptic receptors on neurons located in the striatum, nucleus accumbens, hippocampus, neocortex, and to the spinal cord. Dopamine deficiency in the nigrostriatal pathway is the ultimate cause of the parkinsonian syndrome, i.e. presence of bradykinesia and at least one of rigidity or resting tremor (Postuma et al. 2015).

Neurodegenerative changes in PD are associated with progressive alpha-synuclein aggregation and clinical symptoms developing slowly over time. It has been shown that alpha-synuclein pathology with Lewy bodies is present in gut myenteric plexus and olfactory nerve decades before motor symptoms develop. According to prevailing theory, the progressive alpha-synuclein pathology occurs in a prion-like manner and ultimately affects the entire nervous system. Some neuronal populations appear to be more vulnerable to the alpha-synuclein pathology than other. This is the case of SN dopaminergic neurons, which are prominently affected by neurodegeneration in PD (Poewe et al. 2017). Neither the etiology of the alpha-synuclein related neurodegeneration nor the cause of the vulnerability of dopaminergic cells is currently known. It is however clear that ageing, as well as genetic and environmental factors are involved (Kalia and Lang 2016). Specific mutations (Kalinderi et al. 2016) in genes causing familial PD as well as polymorphisms increasing the risk of PD have been identified. Interestingly, mechanisms of these mutations appear to converge on disrupted synaptic, endosomal, and lysosomal trafficking ultimately leading to overwhelming of cellular disposal mechanisms (Abeliovich and Gitler 2016).

Apparently the development of PD is characterized by three different biochemical dysfunctions, viz. abnormal protein aggregation, inhibition of mitochondrial complex 1, and oxidative stress (Dauer and Przedborski 2003; Tanner et al. 1989). In normal healthy states, aggregates of alpha-synuclein are cleared by autophagy provided adequate activity of leucine-rich repeat kinase 2 (LRRK2) is present (Volpicelli-Daley et al. 2016). Mutations in the LRRK2 gene have been noted in sporadic and in familial PD (Berg et al. 2005). Mutations in other genes, i.e. the SNCA gene (the alpha-synuclein gene), also represent risk factors for PD (Kalinderi et al. 2016).

However, genetic background is considered to account for only about 10% of PD cases, suggesting that other factors play a crucial role in the pathogenesis. History of recent cranial trauma (Fang et al. 2012a) and CNS infections (Fang et al. 2012b) as well as environmental factors such as exposure to fungicides and pesticides, e.g., maneb, rotenone and paraquat (Costello et al. 2009; Tanner et al. 2011) seem to be involved in the pathogenic process. There is ongoing discussion whether chronic low-level exposure to various metals such as manganese may
also be a risk factor for PD (Lucchini et al. 2009). Furthermore, extensive epidemiological research has identified several factors, such as tobacco smoking, drinking tea or coffee, use of NSAID, statins, salbutamol, and physical activity (Yang et al. 2015) to pose a reduced risk to develop PD (Ascherio and Schwarzschild 2016; Barranco Quintana et al. 2009; Noyce et al. 2012). It is an interesting question whether these factors may prevent aggregation of alpha-synuclein itself or protect vulnerable cellular populations from its toxic effects. Indeed, recent research indicates that there is no correlation between Lewy body load and dopaminergic neuronal loss in incidental Lewy body disease and PD cases (Iacono et al. 2015) suggesting that alpha-synuclein pathology does not irrevocably lead to neuronal death.

At present there is no effective cure for PD, and the current treatment is merely symptomatic based on substitution of dopaminergic deficit. Disease-modifying approaches are urgently needed and understanding the effects of protective factors identified by epidemiological studies may bring us closer to this goal.

The present review identifies common mechanism of some preventive measures in PD and highlights their potential role in ameliorating metal-related pathology. We also discuss links between metal exposure, Fe metabolism and DA metabolism.

Dysregulated iron and copper metabolism and oxidative stress in Parkinson’s disease

The accumulation of Fe observed in SN in association with the occurrence of aggregated misfolded protein seems to contribute to the progression of PD (Ward et al. 2014). One theory claims that pathological distributions of Fe and copper (Cu) (Dusek et al. 2015; Genoud et al. 2017; Ward et al. 2014) aggravate oxidative damage and contribute to PD progression. Elevated cytosolic Fe in SN of PD patients has long been associated with neurotoxicity via various mechanisms including deleterious interactions between DA and Fe (Hare and Double 2016). Furthermore, dysmetabolism of Cu with reduced cytosolic fraction of the metal, reflecting reduced activity of the cuproenzyme superoxide dismutase-1 (SOD1) (Genoud et al. 2017) will also increase the oxidative stress in PD (Trist et al. 2018). The pathogenic role of the aggregation of alpha-synuclein, effective as a Cu chaperone, for the SOD1 insufficiency is unclear (Barnham and Bush 2008). The alterations in Fe and Cu distribution appear to occur early in the PD disease process and are therefore not considered to represent merely a reactive redistribution of metals secondary to neuroinflammation (Genoud et al. 2017).

The neurotransmitter precursor L-dopa is synthesized from the amino acid tyrosine by the enzyme complex tyrosine hydroxylase that uses molecular oxygen and Fe(II) as cofactors (Fig. 1). This enzyme complex represents a sensitive biochemical site in the SN. Transition metal ions, including free ions of Fe, manganese, and Cu, can catalyze the generation of ROS around this site, and thereby affect the enzymatic function of tyrosine hydroxylase negatively. Malfunction of tyrosine hydroxylase may further speed up ROS generation, forming a vicious circle of enzymatic dysfunction and ROS generation accelerating nigrostriatal cell death. However, the exact mechanisms of cellular death in PD, starting in the SN pars compacta and subsequently spreading to other CNS regions, are yet not fully known (Kalia and Lang 2016). Environmental pollutants contributing in the PD pathogenesis include 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (Langston and Ballard 1984), paraquat, rotenone, and maneb (Liou et al. 1997; Pezzoli and Cereda 2013; Qi et al. 2014). The toxic effects of rotenone and MPTP are ascribed to their impact on the mitochondrial electron transport chain, as they cause a transport block of electrons in complex 1, leading to generation of ROS (Gao et al. 2003; Smeyne and Jackson-Lewis 2005). Paraquat is another catalyst for the formation of ROS (Bus and Gibson 1984). In rats paraquat toxicity has been associated with Parkinson-like neurodegenerations (Ossowska et al. 2006). One study reported a link between combined exposure to paraquat and Fe in infancy and mid-life Parkinson’s in laboratory mice (Peng et al. 2007). Exposure to maneb, a manganese dithiocarbamate derivative, is associated with increased deposition of transition elements in cerebral regions (Asaeth et al. 1981), thereby apparently causing dopaminergic neurodegeneration (Zhang et al. 2003).

Reduced PD progression by deferiprone and other iron chelators

A characteristic feature of the PD neuropathology is the accumulation of Fe in the degenerating SN (Ward et al. 2014). Although neurodegenerative changes are
widespread in the PD nervous system, increased Fe concentrations is apparently limited to SN (Acosta-Cabronero et al. 2017; Double et al. 2010) where the most pronounced neuronal loss is reported (Barbosa et al. 2015). Interactions between electrophilic Fe(III) ions and an extra-vesicular fraction of DA are assumed to play a critical role in the progressive cellular degeneration, initially creating an unstable Fe(III)–DA-complex, that gives rise to neurotoxic products especially in SN and related sensitive regions of the brain (Hare and Double 2016). The unstable Fe(III)–DA complex appears to bring about the production of \(\alpha\)-quinones (Zhang et al. 2012) and DA-quinones (DA-quinones), as well as 6-hydroxydopamine (6-OHDA). The former compounds are basis of the pigment neuromelanin while the latter agent is a well-known neurotoxin frequently used in animal PD models. Inside the cell, unbound DA-quinones react with the sulfhydryl groups of glutathione (GSH) and protein thiols to form altered protein structures (Stokes et al. 1999) that cause cellular toxicity and microglial activation (Asanuma et al. 2003). It has been suggested that formation of 6-OHDA initiates a cascade of reactions that increases the intracellular labile Fe pool, thus overwhelming protective antioxidant mechanisms (Hare and Double 2016). Other catecholamines also form unstable complexes and toxic products with Cu(II) or Fe(III) (Aaseth et al. 1998). Interestingly, a more stable chelate is formed between Fe(III) and the ephedrine derivative, salbutamol (Fatima 2012), a commonly used anti-asthmatic drug.

Intriguingly, use of the latter drug was associated with significantly decreased risk of developing PD in a large epidemiological trial. Additional analyses have shown that the protective effect is likely based on its documented role as a regulator of the alpha-synuclein gene decreasing its expression (Mittal et al. 2017). A large-scale study is about to be launched studying salbutamol as a disease-modifying agent for PD (Robinson 2017). It would be interesting to see to what extent the chelating properties of salbutamol contribute to its putative neuroprotective effect.

Another metal-binding drug, deferiprone, is a hydroxy ketone pyridine derivative (Fig. 2) effective as an Fe chelating agent in clinical settings and known to cross the blood–brain barrier (Roy et al. 2010). Devos et al. (2014) studied the effect of conservative Fe chelation with 30 mg/kg/day of deferiprone in PD patients. This double-blind placebo-controlled pilot trial showed that 12 months of deferiprone therapy decreased disease progression by three points on the Unified Parkinson’s Disease Rating Scale part III (UPDRS-III) compared to the placebo group. Additionally, quantitative R2* transverse relaxometry MRI technique, a surrogate marker of tissue Fe concentrations, confirmed that deferiprone led to a drop in SN Fe content (Devos et al. 2014). Another placebo-controlled deferiprone trial in PD patients showed only a trend for UPDRS-III improvement in the group using the dose 30 mg/kg/day, but the R2* MRI indicated a decrease of Fe in the dentate and caudate nuclei in the active group compared to placebo (Martin-Bastida et al. 2017). Statistical significance was not reached, maybe related to the short duration (6 months) of this trial.

These results support the hypothesis that conservative Fe chelation may modify natural progression of

![Fig. 2 Chemical structures of proposed protective agents](image-url)
PD. It is possible that Fe chelation may be even more effective when initiated in prodromal stages of PD.

Caffeine: maybe another iron chelator

Postuma et al. (2012) found that patients with PD improved by taking caffeine pills for 2 months. For the study, 61 PD patients with a mean age of 60 years were selected. In six weeks, 30 of the participants received caffeine pills in an amount equivalent to two cups of coffee a day and the remaining 31 subjects got placebo capsules. At the end of the study, the patients who had ingested caffeine reported, in addition to less drowsiness, a general improvement in motor symptoms such as muscle stiffness and movement difficulties (Postuma et al. 2012). A larger multicenter follow up study was however unable to reproduce these findings (Postuma et al. 2017).

Ross et al. (2000) upon analyzing data collected during 30 years of follow-up of 8004 Japanese-American men aged 45–68 enrolled in the study during the period 1965–1968, identified 102 men with PD, and noted that high coffee or caffeine intake was linked to a significantly lower frequency of PD. This effect appeared to be independent of smoking. Their data indicated that the mechanism was related to the caffeine dose and not to other nutrients (Ross et al. 2000). Animal studies (Xu et al. 2016) and meta-analysis (Costa et al. 2010) have confirmed these observations. Another meta-analysis has shown an inverse linear dose–response relationship between PD risk and amount of coffee, tea or caffeine consumed. It was found that maximum protection was reached at about three cups of coffee per day (Qi and Li 2014). In this context the structural similarities between deferiprone and caffeine should be noted (Fig. 2). Protective effects of caffeine may be related to its ability to bind Fe via its nitrogen and oxygen groups, albeit with a lower binding constant than the EDTA-Fe complexes (Andjelković et al. 2006).

Niacin is a protector with metal binding properties

Vitamin B3, or niacin, also known as nicotinic acid, may alleviate certain types of early-onset PD symptoms (Anderson et al. 2008). Niacin has been shown to attenuate neuroinflammation through an action on niacin receptor 1 (NIACR1), also known as GPR109A and may have a therapeutic potential toward PD (Wakade and Chong 2014). Although moderate amounts of niacin are found in a number of foods, including chicken, turkey, beef, peanut and mushrooms, the vitamin can be supplemented in therapeutic doses as tablets. In MPTP exposed rodents, the administration of nicotinamide gave a dose-dependent saving of striatal DA levels and SN neurons (Anderson et al. 2008). Niacin, which is a precursor for nicotinamide adenine dinucleotide (NAD–NADH) needed for DA production, may serve several purposes, i.e., reduce inflammation through NIACR1-related mechanisms, increase DA synthesis in the striatum through NADPH supply and increase NAD/NADH ratio to restore complex I functions in mitochondria. Niacin can also bind transition metal ions including Fe into stable complexes (Al-Saif and Refat 2012).

Nicotine and its neuroprotective mechanisms

Nicotine may have a potential to protect against PD, and pharmaceuticals that target nicotine receptors have been searched for. In particular, the nicotinic alpha-7 receptor, implicated in long-term memory function, has been in the focus of interest (Rang et al. 2003).

Nicotine acts as an agonist to most nicotinic acetylcholine receptors (Malenka et al. 2009), and can be used to improve cognition and alertness (Jasinska et al. 2014). A meta-analysis of 41 placebo-controlled studies concluded that nicotine had a positive effect on motor abilities, orienting attention, and working memory (Heishman et al. 2010).

Using rat embryo tissue, Toulorge et al. (2011) prepared brain cell cultures demonstrating conditions that favored progressive loss of dopaminergic neurons, which also showed distinctive features otherwise characterizing PD, and this group also reported a protective effect of nicotine. In normal mice, nicotine has been found potentially able to rescue dopaminergic neurons, but apparently not in mice without the nicotine receptor (Toulorge et al. 2011).

Although one of the developed nicotine receptor agonists, varenicline, showed only limited protective effect (Bohnen et al. 2009), further research on nicotine receptors and nicotine agonists in PD brings possibilities for early stage neuroprotective treatment (Barreto et al. 2014; Kelton et al. 2000; Quik 2004). Interestingly, nicotine also acts as a metal-chelating
agent, with high affinity for Fe(III) (Fazary 2017). Thus, it is tempting here to forward the hypothesis that the PD protecting potential of nicotine is not merely related to its effects on the receptors, but also to its ability to pass the blood–brain barrier better than other chelators and thus act as an intra-neuronal Fe chelating agent (Zhang et al. 2006).

Glutathione and glutathione peroxidase protect against neurodegeneration

Another approach to ameliorate cellular deterioration caused by ROS in PD is to raise the intracellular levels of the tripeptide glutathione (GSH). Antioxidant defenses in SN are relatively low, compared to other regions of CNS, due to low levels of GSH, particularly during the early stages of PD when extravesicular DA and its degradation products may act as a GSH depleting agents (Pearce et al. 1997; Stokes et al. 1999). N-acetylcysteine (NAC) shows antioxidant properties by restoring cellular GSH, which participate in important endogenous antioxidant systems. In experimental studies NAC has been reported to protect against PD development (Rahimmi et al. 2015).

Glutathione acts either alone or together with an appropriate enzyme system, viz. glutathione peroxidases (GPXs), to reduce ROS. Also, GSH detoxifies xenobiotics and maintains sulphhydril proteins in a reduced state (Meister and Anderson 1983). The antioxidant characteristics of GSH have been demonstrated in several models of oxidative stress, including models using buthionine-sulfoximine (BSO) to deplete GSH (Wullner et al. 1996). In these studies, the GSH depletion increased oxidative stress in whole cells as well as in mitochondrial fractions. Depletion of GSH with BSO potentiated the MPTP-induced tyrosine hydroxylase-positive neuron death in pars compacta of SN (Wullner et al. 1996). Furthermore, NAC treatment after MPTP or rotenone exposure in the GSH-depleted models, restored mitochondrial complex 1 and protected against DA loss in SN (Chinta et al. 2006).

It is tempting to suggest that supplementation with NAC in adequate doses to patients with PD may inhibit disease progression.

In vivo, GSH exerts most of its anti-oxidative functions as a cofactor to the GPX family of enzymes. GPXs are a group of selenium-containing enzymes capable of reducing toxic peroxides (Rotruck et al. 1973); GPX1 is present in both neurons and glial cells (Power and Blumbergs 2009). Overexpression of GPX decreases the amount of neuron loss in neurotoxic conditions (Wang et al. 2003). An immunocytochemical study of GPX1 expression showed that dopaminergic neurons in the SN expressed low levels of this protein, while other regions not affected in PD, expressed higher levels (Trepanier et al. 1996). In an experimental model of GPX1-deficient PD-mice challenged with MPTP, DA levels in vulnerable regions decreased (Klivenyi et al. 2000). However, in cortical samples taken from PD patients, GPX3 and GPX4 proteins were elevated compared to control subjects (Blackinton et al. 2009), presumably reflecting a protective response.

A marginal or deficient selenium status as is reported from Scandinavian regions (Alehagen et al. 2016; Ellingsen et al. 2009) and other parts of Europe involve a deficient GPX-dependent protection (Alehagen et al. 2017), also with regard to nigrostriatal functions. To the knowledge of the authors, clinical studies with selenium supplementation in early stages of PD in these regions have yet not been carried out.

Non-steroidal anti-inflammatory drugs

Neuroinflammation contributes to degeneration of the dopaminergic nigrostriatal pathway in PD (Vivekanantham et al. 2015) through mechanisms of microglial activation. Pro-inflammatory phenotype of microglia is promoted by extracellular alpha-synuclein aggregates and neuromelanin complexes released from dying neurons (McGeer et al. 1988). Neuromelanin contains high concentration of various metals, namely Fe, Cu and Mn that may themselves contribute to inflammation (Tansey and Goldberg 2010). Neuroinflammation in PD is rather widespread as increased inflammatory markers, such as TNFα, IFNγ, IL-6, IL-1β, and other cytokines are consistently detected in serum and cerebrospinal fluid of PD patients (Brodacki et al. 2008). Neuroinflammation is also an early event in neuronal degeneration since microglial activation has been documented by PET in patients with isolated REM sleep behavioral disorder, considered a prodromal synucleinopathy (Stokholm et al. 2017). Given that several genes causing PD, namely LRRK2, GBA, and SNCA, are expressed predominantly in immune cells and/or are involved in regulating inflammatory response, the emerging hypothesis is that inflammatory dysregulation is a

Springer
primary trigger of neurodegeneration (Dzamko et al. 2015). However, it is not clear to what extent is the activation of immune cells is deleterious with respect to disease progression. On one side, microglial phagocytosis may clear abnormal protein aggregates, on the other side, neurotoxic effects of chronic inflammatory reaction may accelerate neuronal loss (Deleidi and Gasser 2013).

According to epidemiological data, non-steroidal anti-inflammatory drugs (NSAIDs) can reduce the risk of developing PD (Asanuma et al. 2004; Chen et al. 2003; Wahner et al. 2007). These results are apparently in line with immunocytotoxic theories of neurodegeneration, and a neuroprotective effect of NSAID was initially ascribed to cyclooxygenase type-2 inhibition (Teismann et al. 2003). However, other studies did not confirm reduced PD risk in the NSAID users compared to controls (Becker et al. 2011; Etminan and Suissa 2006). Later studies detailed the effect of NSAID, and Wahner et al. (2007) reported that reduced risk of getting PD in NSAID users was seen only among regular users and the effect was particularly strong (OR 0.44) in people who regularly used non-aspirin NSAIDs (Wahner et al. 2007). A meta-analysis by Gagne and Power (2010) revealed only a moderately reduced risk of about 15% in non-aspirin NSAID users while no protective effect was observed in aspirin users (Gagne and Power 2010). More specifically, only regular use of ibuprofen was associated with significant reduction of PD risk (pooled OR 0.73) in a study and meta-analysis of several NSAIDs (Gao et al. 2003). Taken together, the fact that ibuprofen use, but not use of other NSAIDs, was associated with lower PD risk suggests mechanisms other than a generic anti-inflammatory activity. It is possible that only some few NSAIDs act protective, owing to their ability to form Cu, manganese or Fe chelates (Duncan and White 2012). Interestingly, it was suggested that ibuprofen possesses Fe chelating (Kennedy et al. 1990) or hydroxyl scavenging (Hamburger and McCay 1990) properties. Of interest is also that some Cu-chelates of NSAIDs appear to show SOD-mimetic activity (Roberts and Robinson 1985).

Exercise

Parkinson’s disease can be delayed, or its consequences attenuated through regular safe physical activity. Recent scientific studies suggest a combination of aerobic activities, strength training from moderate to high intensity, as well as balance training, gait training, functional activities and exercises that require agility (Fisher et al. 2008; Goodwin et al. 2008). Experimental studies indicate that the inflammatory response is reduced, insulin sensitivity improved and damage to dopaminergic neurons reduced when exercise is combined with intermittent fasting (Mattson 2014).

Physiotherapeutic treatment should be started as soon as the diagnosis is confirmed and is a good way to help stimulate movement and quality of life as it improves the strength, coordination, and amplitude of the movements, i.e., by reducing the otherwise inexorable imbalance characterizing the progressive disease, thereby preventing contractures and falls (Ahlskog 2011).

Conclusion

Environmental factors including exposure to metals, pesticides and drugs account for the majority of cases of Parkinson’s disease. Excessive oxidative stress accentuated by iron accumulation and abnormal protein aggregation in the nigrostriatal region of the brain are primary events in the development of the disease that need to be addressed by preventive measures. Iron is a necessary cofactor for the enzyme tyrosine hydroxylase responsible for DA synthesis, and accumulation of Fe in the SN deteriorates the function of tyrosine hydroxylase. Metal binding substances e.g. Deferiprone mobilize Fe from the SN possibly providing prevention. Caffeine, niacin, nicotine and salbutamol also seem to protect against progression by similar mechanisms. Supplementation with NAC together with selenium for optimal glutathione synthesis is recommended to reduce oxidative damage to sensitive SN cells.

Acknowledgements This work was supported by Ulla-Carin Lindquist ALS-Foundation, Magnus Bergvall foundation, Sweden, Innlandet Hospital Trust, Norway and by the Czech Science Foundation (Grant No. 16-07879S) and Czech Ministry of Health (Grant No. 15-25602A). All authors contributed equally to the manuscript. The study sponsors had no role in the writing of this review, nor in the decision to submit the paper for publication.
Compliance with ethical standards

Conflicts of interest  The authors declare no conflicts of interest.

Open Access  This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

Aaseth J, Alexander J, Wannag A (1981) Effect of thiocarbamate derivatives on copper, zinc, and mercury distribution in rats and mice. Arch Toxicol 48:29–39
Aaseth J, Korkina LG, Afanas’ev IB (1998) Hemolytic activity of copper sulfate as influenced by epinephrine and chelating thiols. Acta Pharmacol Sin 19:203–206
Abeliovich A, Gitler AD (2016) Defects in trafficking bridge Parkinson’s disease pathology and genetics. Nature 539:207–216. https://doi.org/10.1038/nature2014
Acosta-Cabronero J, Cardenas-Blanco A, Betts MJ, Butryn M, Valdes-Herrera JP, Galazky I, Nestor PJ (2017) The whole-brain pattern of magnetic susceptibility perturbations in Parkinson’s disease. Brain 140:118–131. https://doi.org/10.1093/brain/aww278
Ahlskog JE (2011) Does vigorous exercise have a neuroprotective effect in Parkinson disease? Neurology 77:288–294. https://doi.org/10.1212/WNL.0b013e318225ab6
Alehagen U, Johansson P, Bjornstedt M, Rosen A, Post C, Aaseth J (2016) Relatively high mortality risk in elderly Swedish subjects with low selenium status. Eur J Clin Nutr 70:91–96. https://doi.org/10.1038/ejcn.2015.92
Alehagen U, Johansson P, Aaseth J, Alexander J, Brismar K (2017) Increase in insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding protein 1 after supplementation with selenium and coenzyme Q10. A prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens. PLoS ONE 12:e0178614. https://doi.org/10.1371/journal.pone.0178614
Al-Saif FA, Refat MS (2012) Ten metal complexes of vitamin B3/niacin: Spectroscopic, thermal, antibacterial, antifungal, cytotoxicity and antimutator studies of Mn(II), Fe(III), Co(II), Ni(II), Cu(II), Zn(II), Pd(II), Cd(II), Ptx(IV) and Au(III) complexes. J Mol Solid 1021:40–52
Anderson DW, Bradbury KA, Schneider JS (2008) Broad neuroprotective profile of nicotinamide in different mouse models of MPTP-induced parkinsonism. Eur J Neurosci 28:610–617. https://doi.org/10.1111/j.1460-9568.2008.06356.x
Andjelkovic M, Van Camp J, De Meulenaer B, Depaemelaere G, Socaciu C, Verloo M, Verhe R (2006) Iron-chelation properties of phenolic acids bearing catechol and galloyl groups. Food Chem 98:23–31
Asanuma M, Miyazaki I, Ogawa N (2003) Dopamine- or l-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson’s disease. Neurotox Res 5:165–176
Asanuma M, Miyazaki I, Ogawa N (2004) Neuroprotective effects of nonsteroidal anti-inflammatory drugs on neurodegenerative diseases. Curr Pharm Des 10:695–700
Ascherio A, Schwarzschild MA (2016) The epidemiology of Parkinson’s disease: risk factors and prevention. Lancet Neurol 15:1257–1272. https://doi.org/10.1016/S1474-4422(16)30230-7
Barbosa JH, Santos AC, Tumas V, Liu M, Zheng W, Haacke EM, Salmon CE (2015) Quantifying brain iron deposition in patients with Parkinson’s disease using quantitative susceptibility mapping, R2 and R2*. Magn Reson Imaging 33:559–565. https://doi.org/10.1016/j.mri.2015.02.021
Barnham KJ, Bush AI (2008) Metals in Alzheimer’s and Parkinson’s diseases. Curr Opin Chem Biol 12:222–228. https://doi.org/10.1016/j.cbpa.2008.02.019
Barranco Quintana JL, Allam MF, Del Castillo AS, Navajas RF (2009) Parkinson’s disease and tea: a quantitative review. J Am Coll Nutr 28:1–6
Barreto GE, Iarkov A, Moran VE (2014) Beneficial effects of nicotine, cotinine and its metabolites as potential agents for Parkinson’s disease. Front Aging Neurosci 6:340. https://doi.org/10.3389/fnagi.2014.00340
Becker C, Jick SS, Meier CR (2011) NSAID use and risk of Parkinson disease: a population-based case–control study. Eur J Neurol 18:1336–1342. https://doi.org/10.1111/j.1468-1331.2011.03399.x
Berg D et al (2005) Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson’s disease. Brain 128:3000–3011. https://doi.org/10.1093/brain/awh666
Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitlberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington, clinical, morphological and neurochemical correlations. J Neurol Sci 20:415–455
Blackinton J et al (2009) Post-transcriptional regulation of mRNA associated with DJ-1 in sporadic Parkinson disease. Neurosci Lett 452:8–11. https://doi.org/10.1016/j.neulet.2008.12.053
Bohnen NI, Muller ML, Koepp RA, Studenski SA, Kilbourn MA, Frey KA, Albin RL (2009) History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology 73:1670–1676. https://doi.org/10.1212/WNL.0b013e3181c1ded6
Brodacki B, Staszewski J, Toczylowska B, Kozlowska E, Drela N, Chalimoniu M, Stepień A (2008) Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFα, and IFNγ concentrations are elevated in patients with atypical and idiopathic parkinsonism. Neuromol Lett 441:158–162. https://doi.org/10.1016/j.neulet.2008.06.040
Bus JS, Gibson JE (1984) Paracetamol: model for oxidant-initiated toxicity. Environ Health Perspect 55:37–46
Chen H et al (2003) Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 60:1059–1064. https://doi.org/10.1001/archneur.60.8.1059
Chinta SJ, Kumar JM, Zhang H, Forman HJ, Andersen JK (2006) Up-regulation of gamma-glutamyl transpeptidase activity following glutathione depletion has a
compensatory rather than an inhibitory effect on mitochondrial complex I activity: implications for Parkinson’s disease. Free Radic Biol Med 40:1557–1563. https://doi.org/10.1016/j.freeradbiomed.2005.12.023

Costa J, Lunet N, Santos C, Santos J, Vaz-Carneiro A (2010) Caffeine exposure and the risk of Parkinson’s disease: a systematic review and meta-analysis of observational studies. JAD 20(Suppl 1):S221–238. https://doi.org/10.3233/JAD-2010-091525

Costello S, Cockburn J, Zhang X, Ritz B (2009) Parkinson’s disease and residential exposure to maneb and paraquat from agricultural applications in the central valley of California. Am J Epidemiol 169:919–926. https://doi.org/10.1093/aje/kwp006

Dauer W, Przedborski S (2003) Parkinson’s disease: mechanisms and models. Neuron 39:889–909

Deleidi M, Gasser T (2013) The role of inflammation in sporadic and familial Parkinson’s disease. CMLS 70:4259–4273. https://doi.org/10.1007/s00018-013-1352-y

Devos D et al (2014) Targeting chelatable iron as a therapeutic modality in Parkinson’s disease. Antioxid Redox Signal 21:195–210. https://doi.org/10.1089/ars.2013.5593

Double KL, Reyes S, Werry EL, Halliday GM (2010) Selective cell death in neurodegeneration: why are some neurons spared in vulnerable regions? Prog Neurobiol 92:316–329. https://doi.org/10.1016/j.pneurobio.2010.06.001

Duncan C, White AR (2012) Copper complexes as therapeutic agents. Metallomics 4:127–138. https://doi.org/10.1039/c2mt00174h

Dusek P, Roos PM, Litwin T, Schneider SA, Flaten TP, Aaseth J (2009) The neurotoxicity of iron, copper and manganese in Parkinson’s and Wilson’s diseases. J Trace Elem Med Biol 31:193–203. https://doi.org/10.1016/j.jtemb.2014.05.007

Dzamko N, Geczy CL, Halliday GM (2015) Inflammation is genetically implicated in Parkinson’s disease. Neuroscience 302:89–102. https://doi.org/10.1016/j.neuroscience.2014.10.028

Ellingsen DG, Thomassen Y, Rustad P, Molander P, Aaseth J (2009) The time-trend and the relation between smoking and circulating selenium concentrations in Norway. J Trace Elem Med Biol 23:107–115. https://doi.org/10.1016/j.jtemb.2009.01.004

Eltiman M, Sussa S (2006) NSAID use and the risk of Parkinson’s disease. Curr Drug Saf 1:223–225

Fang F, Chen H, Feldman AL, Kamel F, Ye W, Wirdefeldt K (2012a) Head injury and Parkinson’s disease: a population-based study. Mov Disord 27:1632–1635. https://doi.org/10.1002/mds.25143

Fang F, Wirdefeldt K, Jacks A, Kamel F, Ye W, Chen H (2012b) CNS infections, sepsis and risk of Parkinson’s disease. Int J Epidemiol 41:1042–1049. https://doi.org/10.1093/ije/dys052

Fatima N (2012) Complexation, stability and stoichiometry of iron (III) with salbutamol (active ingredient of asthma drug Ventolin®). Pak J Biol Sci 2:91–98

Fazary AE (2017) Metal complexes of nicotine: a group of negligible compounds, vol 8. Pelagia Research Library, Abha

Fisher BE et al (2008) The effect of exercise training in improving motor performance and corticomotor excitability in people with early Parkinson’s disease. Arch Phys Med Rehabil 89:1221–1229. https://doi.org/10.1016/j.apmr.2008.01.013

Gagne JJ, Power MC (2010) Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. Neurology 74:995–1002. https://doi.org/10.1212/WNL.0b013e3181d5a4h

Gao HM, Liu B, Hong JS (2003) Critical role for microglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons. J Neurosci 23:6181–6187

Genoud S et al (2017) Subcellular compartmentalisation of copper, iron, manganese, and zinc in the Parkinson’s disease brain. Metallomics 9:1447–1455. https://doi.org/10.1039/c7mt00244k

Global Burden of Disease Cancer C et al (2017) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol 3:524–548. https://doi.org/10.1001/jamaoncol.2016.5688

Goodwin VA, Richards SH, Taylor RS, Taylor AH, Campbell JL (2008) The effectiveness of exercise interventions for people with Parkinson’s disease: a systematic review and meta-analysis. Mov Disord 23:631–640. https://doi.org/10.1002/mds.21922

Hamburger SA, McCoy PB (1990) Spin trapping of ibuprofen radicals: evidence that ibuprofen is a hydroxyl radical scavenger. Free Radic Res Commun 3:337–342

Hare DJ, Double KL (2016) Iron and dopamine: a toxic couple. J Neurochem 139:1026–1035. https://doi.org/10.1093/jnci/dww022

Heishman SJ, Kleykamp BA, Singleton EG (2010) Meta-analysis of the acute effects of nicotine and smoking on human performance. Psychopharmacology 210:453–469. https://doi.org/10.1007/s00213-010-1848-1

Iacono D, Geraci-Erck M, Rabin ML, Adler CH, Serrano G, Beach TG, Kurlan R (2015) Parkinson disease and incidental Lewy body disease: just a question of time? Neurology 85:1670–1679. https://doi.org/10.1212/WNL.000000000002102

Jasinska AJ, Zorick T, Brody AL, Stein EA (2014) Dual role of nicotine in addiction and cognition: a review of neuromaging studies in humans. Neuropharmacology 74:995–1002. https://doi.org/10.1016/j.neuropharm.2013.02.015

Kalinderi K, Bostantjopoulou S, Sidani L (2016) The genetic background of Parkinson’s disease: current progress and future prospects. Acta Neurol Scand 134:314–326. https://doi.org/10.1111/ane.12563

Kelton MC, Kahn HJ, Conrath CL, Newhouse PA (2000) The effects of caffeine exposure and the risk of Parkinson’s disease. Curr Med Res Opin 3:524–548. https://doi.org/10.1007/s00213-010-1848-1
Klivenyi P et al (2000) Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. J Neurosci 20:1–7

Langston JW, Ballard P (1984) Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson’s disease. Can J Neurol Sci 11:160–165

Liou HH, Tsai MC, Jeng JS, Chang YC, Chen SY, Chen RC (1997) Environmental risk factors and Parkinson’s disease: a case-control study in Taiwan. Neurology 48:1583–1588

Lucchini RG, Martin CJ, Doney BC (2009) From manganism to manganese-induced parkinsonism: a conceptual model based on the evolution of exposure. NeuroMol Med 11:311–321. https://doi.org/10.1007/s12017-009-8108-8

Malenka RC, Nestler EJ, Hyman SE (2009) In: Molecular neuropharmacology: a foundation for clinical neuroscience, 2nd ed. McGraw-Hill Medical, New York, p. 234

Martin-Bastida A et al (2017) Brain iron chelation by deferiprone in a phase 2 randomised double-blind placebo controlled clinical trial in Parkinson’s disease. Sci Rep 7:1398. https://doi.org/10.1038/s41598-017-01402-2

Mattson MP (2014) Interventions that improve body and brain bioenergetics for Parkinson’s disease risk reduction and therapy. J Parkinson’s Dis 4:1–13. https://doi.org/10.3233/JPD-130335

McGeer PL, Itagaki S, Boyes BE, McGeer EG (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology 38:1285–1291

Meister A, Anderson ME (1983) Glutathione. Ann Rev Biochem 52:711–760. https://doi.org/10.1146/annurev.bi.52.070183.003431

Mittal S et al (2017) Caffeine as symptomatic treatment for Parkinson disease: a randomized controlled trial. Neurology 89:1795–1803. https://doi.org/10.1212/WNL.0000000000004568

Poewe W et al (2017) Parkinson disease. Nat Rev Dis Primers 3:17013. https://doi.org/10.1038/nrdp.2017.13

Postuma RB et al (2012) Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology 79:651–658. https://doi.org/10.1212/WNL.0b013e318263570d

Power JH, Blumbergs PC (2009) Cellular glutathione peroxidase in human brain: cellular distribution, and its potential role in the degradation of Lewy bodies in Parkinson’s disease and dementia with Lewy bodies. Acta Neuropathol 117:63–73. https://doi.org/10.1007/s00401-008-0438-3

Qi H, Li S (2014) Dose-response meta-analysis on coffee, tea and caffeine consumption with risk of Parkinson’s disease. Geriatr Gerontol Int 14:430–439. https://doi.org/10.1111/ggi.12123

Qi Z, Miller GW, Voit EO (2014) Rotenone and paraquat perturb dopamine metabolism: a computational analysis of pesticide toxicity. Toxicology 315:92–101. https://doi.org/10.1016/j.tox.2013.11.003

Quik M (2004) Smoking, nicotine and Parkinson’s disease. Trends Neurosci 27:561–568. https://doi.org/10.1016/j.tins.2004.06.008

Rahimmi A, Khosrobakhsh F, Izadpanah E, Moloudi MR, Hassanzadeh K (2015) N-acetylcysteine prevents rotenone-induced Parkinson’s disease in rat: an investigation into the interaction of parkin and Drp1 proteins. Brain Res Bull 113:34–40. https://doi.org/10.1016/j.brainresbull.2015.02.007

Rang HP, Dale MM, Ritter JM, Moore PK (2003) Pharmacology. Churchill Livingstone, New York

Roberts NA, Robinson PA (1985) Copper chelates of anti-rheumatic and anti-inflammatory agents: their superoxide dismutase-like activity and stability. Br J Rheumatol 24:128–136

Robinson R (2013) In the pipeline—Parkinson’s disease: why a common asthma drug could be a disease modifier for Parkinson’s disease. Neurology 17:1–23

Ross GW et al (2000) Association of coffee and caffeine intake with the risk of Parkinson disease. Jama 283:2674–2679

Roy S, Preston JE, Hider RC, Ma YM (2010) Glucosylated deferiprone and its brain uptake: implications for developing glucosylated hydroxypyridinone analogues intended to cross the blood–brain barrier. J Med Chem 53:5886–5889. https://doi.org/10.1021/jm100380k

Smeinye RJ, Jackson-Lewis V (2005) The MPTP model of Parkinson’s disease Brain research. Mol Brain Res 134:57–66. https://doi.org/10.1016/j.molbrainres.2004.09.017

Springer
Stokes AH, Hastings TG, Vrana KE (1999) Cytotoxic and genotoxic potential of dopamine. J Neurosci Res 55:659–665.

Stokholm MG et al (2017) Assessment of neuroinflammation in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case–control study. Lancet Neurol 16:789–796. https://doi.org/10.1016/S1474-4422(17)30173-4

Tanner CM et al (1989) Environmental factors and Parkinson’s disease: a case-control study in China. Neurology 39:660–664

Tanner CM et al (2011) Rotenone, paraquat, and Parkinson’s disease. Environ Health Perspect 119:866–872. https://doi.org/10.1289/ehp.1002839

Tansey MG, Goldberg MS (2010) Neuroinflammation in Parkinson’s disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 37:510–518. https://doi.org/10.1016/j.nbd.2009.11.004

Teismann P, Vila M, Choi DK, Tieu K, Wu DC, Jackson-Lewis V, Przedborski S (2003) COX-2 and neurodegeneration in Parkinson’s disease. Ann N Y Acad Sci 991:272–277

Toulorge D, Guerreiro S, Hild A, Maskos U, Hirsch EC, Michel PP (2011) Neuroprotection of midbrain dopamine neurons by nicotine is gated by cytoplasmic Ca \(^{2+}\). FASEB J 25:2563–2573. https://doi.org/10.1096/fj.11-182824

Trepanier G, Furling D, Puymirat J, Mirault ME (1996) Immunocytochemical localization of seleno-glutathione peroxidase in the adult mouse brain. Neuroscience 75:231–243

Trist BG et al (2018) Accumulation of dysfunctional SOD1 protein in Parkinson’s disease is not associated with mutations in the SOD1 gene. Acta Neuropathol 135:155–156. https://doi.org/10.1007/s00401-017-1779-6

Vivekanantham S, Shah S, Dewji R, Dewji A, Khatri C, Olo- gunde R (2015) Neuroinflammation in Parkinson’s disease: role in neurodegeneration and tissue repair. Int J Neurosci 125:717–725. https://doi.org/10.3109/00207454.2014.982795

Volpicelli-Daley LA et al (2016) G2019S-LRRK2 expression augments alpha-synuclein sequestration into inclusions in neurons. J Neurosci 36:7415–7427. https://doi.org/10.1523/JNEUROSCI.3642-15.2016

Wahner AD, Bronstein JM, Bordelon YM, Ritz B (2007) Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease. Neurology 69:1836–1842. https://doi.org/10.1212/01.wnl.0000279519.99344.ad

Wakade C, Chong R (2014) A novel treatment target for Parkinson’s disease. J Neurol Sci 347:34–38. https://doi.org/10.1016/j.jns.2014.10.024

Wang H, Cheng E, Brooke S, Chang P, Sapolsky R (2003) Over-expression of antioxidant enzymes protects cultured hippocampal and cortical neurons from necrotic insults. J Neurochem 87:1527–1534

Ward RJ, Zucca FA, Duyn JH, Crigton RR, Zecca L (2014) The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol 13:1045–1060. https://doi.org/10.1016/S1474-4422(14)70117-6

Wullner U et al (1996) Glutathione depletion potentiates MPTP and MPP+ toxicity in nigral dopaminergic neurons. NeuroReport 7:921–923

Xu K, Di Luca DG, Ortu M, Xu Y, Chen JF, Schwartzschild MA (2016) Neuroprotection by caffeine in the MPTP model of Parkinson’s disease and its dependence on adenosine A2A receptors. Neuroscience 322:129–137. https://doi.org/10.1016/j.neuroscience.2016.02.035

Yang F, Trolle Lagerros Y, Bellocco R, Adami HO, Fang F, Pedersen NL, Wirdefeldt K (2015) Physical activity and risk of Parkinson’s disease in the Swedish National March Cohort. Brain 138:269–275. https://doi.org/10.1093/brain/awu323

Zhang J, Fitsanakis VA, Gu G, Jing D, Ao M, Amarnath V, Montine TJ (2003) Manganese ethylene-bis-dithiocarbamate and selective dopaminergic neurodegeneration in rat: a link through mitochondrial dysfunction. J Neurochem 84:336–346

Zhang J et al (2006) Nicotine attenuates beta-amyloid-induced neurotoxicity by regulating metal homeostasis. FASEB J 20:1212–1214. https://doi.org/10.1096/fj.05-5214fje

Zhang L, Yagnik G, Jiang D, Shi S, Chang P, Zhou F (2012) Separation of intermediates of iron-catalyzed dopamine oxidation reactions using reversed-phase ion-pairing chromatography coupled in tandem with UV-visible and ESI-MS detections. J Chromatograph B Anal Technol Biomed Life Sci 911:55–58. https://doi.org/10.1016/j.jchromb.2012.10.026